Gout is the most common inflammatory arthritis worldwide. Its principal risk factor is hyperuricaemia. While gout has been described in HIV patients and numerous more outdated anti-retroviral therapies (ARTs) have been implicated, there have been few recent studies. Our case-control study investigated the prevalence of and risk factors for gout in an established HIV cohort. Cases were identified from database searches using key search terms, with two age-and gendermatched controls. These were compared for demographic factors, co-morbidities, HIV factors and ART exposure. Forty-five cases with gout were identified (point prevalence 2.2%). All were male and were more likely than controls to be of black African origin. Hypertension was associated with an almost five-fold increased gout risk (OR 4.8, 95% CI 1.8-12.4). No individual drug or ART class was associated with gout in this study but exposure to non-nucleoside reverse transcriptase inhibitors had a significantly protective effect against the risk of gout (OR 0.3, 95% CI 0.1-0.9). Our data suggest that gout is common in HIV patients and that the traditional risk factors, especially hypertension, play a key role. Gout and hyperuricaemia should be regarded as a biomarker of cardiovascular disease in HIV patients as they are in the general population.
Background
Combination anti-retroviral therapy (ART) has transformed the prognosis of HIV infection and normalised life expectancy. However, the consequence is a growing population of people living with HIV (PLHIV) with a chronic long-term condition associated with co-morbidities related to the virus and/or its therapy. Among the most common co-morbidities recognised are dyslipidaemias, hypertension, insulin resistance and diabetes mellitus, all of which are clinical features of the metabolic syndrome. 1 Hyperuricaemia is another recognised manifestation of the metabolic syndrome and is the principal risk factor for gout, the most prevalent inflammatory arthritis worldwide. Gout is a relapsing, remitting painful arthritis which causes substantial morbidity and impaired quality of life. 2, 3 Among the general population, there is evidence that the prevalence of gout is increasing particularly among older men, aged >65 years. 4 There are limited data specifically on gout in PLHIV. One study which utilised exploratory factor methods to investigate patterns of multimorbidity in PLHIV included a diagnosis of gout as part of a 'metabolic' cluster pattern of disease and reported a point prevalence of 2% (95% CI 1.6-2.9%). 5 In addition, there have been a number of case reports published. [6] [7] [8] [9] [10] [11] Observational studies that have estimated the prevalence of gout in their HIV-positive patients have reported rates ranging between 0.4% in Nigeria 12 and 1% among patients attending a tertiary referral centre in India. 13 One UK study investigating the risk of infectious diseases among people with gout found that 0.1% of people with gout in the Clinical Practice Research Datalink (a large representative primary care database) had co-existent HIV. 14 Some, but not all studies have implicated different ARTs, and, in two case reports, gout has been described as an 'immune reconstitution' phenomenon, occurring in ART-naı¨ve patients four weeks after onset of an ART regimen. 10, 11 Although there is a paucity of literature on gout and HIV, there is more information about serum urate and HIV, since uric acid excretion is frequently measured in people receiving ART at risk of proximal renal tubule dysfunction. Hyperuricaemia was first described in HIV by Medina-Rodriguez et al., 15 when they reported a prevalence rate of 41% among 74 HIV-positive cases, as compared with 0% among 72 matched controls. Similar findings were reported by other colleagues. [16] [17] [18] Since the development of ART, hyperuricaemia has been reported with the nucleoside reverse transcriptase inhibitors didanosine and stavudine and the protease inhibitor, ritonavir.
Given the important relationship between serum urate and the metabolic syndrome, and population data suggesting that gout is becoming more common, the aim of this study was to explore the prevalence of and risk factors for gout in a large outpatient cohort of PLHIV using a matched case-control study design.
Methods
Ethical permission for this study was granted by the Brighton Local Research Ethics Committee (REC number: 12/LO/1421).
This case-control study was performed in 2012-2013. All subjects were registered for outpatient HIV care at one centre in the South of England, UK. All correspondence and test results for this cohort are digitised into a clinical database which is searchable. In total, the records of 2042 PLHIV were available at the time of this study. We used the keywords: 'gout', 'hyperuricaemia' and 'uric acid', to search the database for any subjects who might be eligible as cases for this study. In addition, one rheumatologist provided clinical care for all HIV-positive patients developing rheumatological symptoms at this Centre for the past eight years. The clinical database of this rheumatologist was also interrogated for cases and used to validate the search technique. The full clinical case notes were extracted for any individual identified by the preliminary search strategy. People were confirmed as cases if there was evidence that they had been diagnosed from a convincing history and a clinical examination by either a primary or secondary care clinician. For each case, two controls were identified, selected from the HIV outpatient database using a random number generator method (once matched for gender and age [AE5 years]).
The HIV database and patient notes were reviewed for every case and control. Data were extracted onto a pre-defined pro forma designed to collect information about demography (age, gender, ethnicity, sexual orientation and occupation); lifestyle (smoking and alcohol); co-morbidities (hypertension, dyslipidaemias, diabetes mellitus, renal disease); medication relevant to gout (NSAIDS, colchicine, allopurinol, other gout treatment, loop diuretic, thiazide diuretic, low-dose salicylate, nicotinic acid, pyrazinamide, cyclosporine, ethambutol, vitamin B12, prednisolone); blood pressure and body mass index (BMI) and episodes of 'arthritis', 'hot, swollen joint' or confirmed gout episodes.
HIV-specific data were also collected including duration since diagnosis, mode of transmission, World Health Organisation clinical stage of HIV infection, ever exposure to ART and type and duration of exposure to different classes of ART, and nadir and most recent CD4 cell count and viral load. In addition, the results of relevant blood tests were extracted, including full blood count, urea and electrolytes, liver function tests, lipid profile, urine protein:creatinine ratio, uric acid (most recent values).
Basic summary statistics were used to describe differences in demographic characteristics, HIV factors, co-morbidities and relevant drug therapies between cases and controls. Comparisons were made using Fisher's exact tests, given the sample size and that the values in some of the cells of the contingency tables were <5. The same approach was used to compare ART use among cases and controls. From the univariate analyses, we derived a multivariate conditional logistic regression model using forward logistic regression, keeping factors which were significantly associated with the risk of being a case (p < 0.1), independently of other variables. Analyses were conducted with Stata statistical software (v. 14.0) (StataCorp LP, College Station, Texas, USA).
Results
In total, 45 HIV-positive patients were identified with a diagnosis of gout among the total cohort of 2042 registered on the database (estimated point prevalence 2.2%, 95% CI 1.6-2.9%). All of the cases identified were male. The mean age of cases was 56 years, 84% were white Caucasian and 9% black African. Their overall median duration of HIV infection was 160 months and all had acquired HIV through sexual contact (mostly men who have sex with men, 'MSM'). The majority, 41/45 (91%) were currently taking ART. Serum urate levels had been measured within the past 12 months for 26/45 (58%) cases and the average mean serum urate was 0.40 mmol/l (reference range in our laboratory: 0.20-0.42 mmol/l).
For each case, two age-matched controls were identified (Table 1) . A comparison of the demographic and HIV factors of the selected controls with the main database population showed that they were a representative sample (data not shown). The face validity of our search strategy was explored by comparison of the 45 cases with the 90 controls for the following gout treatments: naproxen, diclofenac, colchicine and allopurinol. As expected, cases were highly significantly more likely to report use of each of these drugs when compared with controls and 18/45 (40%) of cases were currently taking allopurinol, as compared with no controls (p < 0.001). Moreover, cases were more likely to have ever been exposed to loop diuretics (p ¼ 0.004) and to be currently taking thiazide diuretics (p ¼ 0.008) than controls. More of the cases had evidence of exposure to ethambutol and pyrazinamide but the numbers were small and did not attain statistical significance. There were significantly more non-Caucasians among cases (6.6%) than among the controls (4.4%) (p ¼ 0.02). Cases were, on average, 10.5 kg heavier than controls (88.0 versus 77.5 kg, p < 0.001) with more adiposity as defined by BMI (p ¼ 0.006). The cases were more likely to have been diagnosed (p ¼ 0.002) and treated (p ¼ 0.002) for hypertension and we found that the most recent average systolic and diastolic blood pressure readings were 4 mmHg higher in the cases than controls but these differences were not statistically significant. Cases were also more likely to have ever been treated for hyper-triglyceridaemia (p ¼ 0.02) but there were no other differences in prevalence of diagnosis or treatment for dyslipidaemia, diabetes mellitus or renal disease between groups.
A comparison of the HIV status of cases and controls showed no significant differences between cases and controls for duration of HIV infection since diagnosis, latest viral load, detectable versus not detectable viral activity, proportion of patients exposed or not exposed to ART, latest CD4þ or nadir CD4þ.
A comparison of the ART use among cases and controls (Table 2 ) by drug class and individual drug suggested that, if anything, controls tended to be slightly more likely to have ever been exposed to nonnucleoside reverse transcriptase inhibitors (NNRTIs) (p ¼ 0.056). We found no association with median duration of exposure to any class of ART and gout, nor was there any relationship between duration of exposure to each class and gout (data not shown).
Exploring current ART, we demonstrated no associations between any individual drug and gout.
Variables associated with the risk of being a case in the univariate analyses were ethnicity, BMI, diagnosis of and treatment for hypertension, treatment for hypertriglyceridaemia and ever exposure to NNRTIs. After forward selection, we identified two factors which remained independently significantly associated with being a case: diagnosis of hypertension (OR 4.8, 95% CI 1.8-12.4) and ever exposure to NNRTI (OR 0.3, 95% CI 0.12-0.88).
Ideally, a diagnosis of gout requires observation of the classical needle-shaped crystals from an aspirate of synovial fluid but, as with other database studies, we were unable to verify the diagnostic criteria applied in each case by the primary or secondary care clinician who had recorded their condition. We cannot therefore rule out that some of the 'controls' matched for age within this study did in fact have undiagnosed prevalent gout, nor could we verify the diagnosis for the 'cases'. To examine the size of any ensuing risk of bias, we compared the availability of a serum urate within the past 12 months and explored the face validity of our search strategy by comparing the exposures of cases and controls to drugs used most commonly for the treatment of gout. Only 1/90 controls had a serum urate within the past 12 months and the result was normal while 26/45 of the gout cases had a serum urate result available to us and the mean values were at the very upper end of the normal range (0.40 mmol/l), consistent with patients diagnosed and treated for gout. Moreover, a high proportion (40%) of the identified cases were current users of allopurinol (the most common treatment for gout in the UK) as compared with no controls, which again lends face validity to the search strategy.
Discussion
In this homogeneous cohort of >2000 PLHIV (90% male, predominantly Caucasian MSM), we estimated a point prevalence rate of 2.2% (95% CI 1.6-2.9%) of gout. The cases identified with gout were all male, were more likely to be non-Caucasian, were heavier with greater adiposity and were more likely to have been diagnosed and treated for hypertension and hypertriglyceridaemia. Indeed, a diagnosis of hypertension was independently associated with a more than fourfold increased risk of gout. Exposure to NNRTIs resulted in a 70% reduction in the risk of gout so that NNRTIs appeared to be protective in relation to gout.
The results of our study need to be considered alongside a number of limitations. Of the cohort eligible for this study, we found only 45 cases diagnosed with gout, and given the multiple testing this relatively small cohort size does impact on the robustness of our findings. It is possible that some patients diagnosed and treated for gout in primary care may not have been identified by a search of the secondary care database and therefore we may be underestimating the true point prevalence in this population.
To our knowledge, this is the first case-control study to explore the prevalence of and risk factors for gout in an HIV cohort. To maximise our power, we chose two age-matched controls for each case. Our power calculations showed that 45 cases and 90 controls matched 1:2 yielded 80% power to detect an odds ratio of 3.0 for an exposure occurring with 25% prevalence among controls. Therefore, we acknowledge that we may still have been relatively underpowered to demonstrate significant associations with some of the individual ART drugs and combinations and indeed with some of the more traditional risk factors for gout. Among the general population, gout is associated with male gender, age, obesity, hypertension, hyperlipidaemia, diabetes mellitus and cardiovascular disease. In this respect, our findings about diagnosis of hypertension and both weight and BMI are consistent with what is expected and with the findings of Patel et al. 19 in another HIV-positive cohort.
Although it is difficult to compare our data with those of other population studies, it would appear that a prevalence rate of 2.2% for gout is in keeping with that found in the general population, especially in the context of a relatively large confidence interval for the current study. For example, a study from the USA on the prevalence of gout among people aged 50-64 years (i.e. older than those in the current study) between 1990 and 1999 reported an age-related prevalence under 2.0%. 2 A study carried out in Germany and the UK reported a prevalence of 1.9%. 3 Where data are available, it appears that the prevalence of gout is increasing, particularly among older men aged >65 years. 2 Gout is very painful and disabling and has marked negative impact on quality of life and has recently been associated with increased mortality. 20 For all these reasons, it is important to be proactive in its identification and treatment.
We found no convincing associations between gout and HIV-associated factors in the current study. A number of early HIV studies reported hyperuricaemia in association with advanced disease, AIDS and malignancies. 15, 17 It has also been suggested that untreated HIV infection per se is a cause of hyperuricaemia but the data are conflicting and there are potentially a number of aetiological mechanisms including increased cell turnover, mitochondrial toxicity, treatment of tuberculosis with pyrazinamide and/or ethambutol, and the increased risk of lymphoproliferative conditions. More data are needed but it is possible that the modern trend for earlier diagnosis and treatment of HIV may reduce the risk of gout in HIV-positive patients.
ART has been implicated as a risk factor for hyperuricaemia over many years. The first drug implicated was the purine analogue didanosine, 21 and this led to the suggestion that serum urate could be used as a marker of compliance with the drug. 22 Walker et al. 18 replicated the association with didanosine but also reported hyperuricaemia associated with stavudine and found that use of both drugs in combination resulted in significantly higher levels of urate when compared to either drug alone. The same study also found an increased risk from zalcitabine and protease inhibitors but suggested a beneficial effect of tenofovir disoproxil fumarate (TDF) on urate and no effect of abacavir. In this study, male gender and stavudine use were the strongest predictors of urate variability. Boosted protease inhibitor use has also been associated with gout in some studies. 9, 16 However, these studies were somewhat confounded by having patients with other risk factors for gout, including patients taking pyrazinamide for TB and patients with lymphoproliferative disorders. It is difficult to directly compare the results of the current study with those reported above since nobody in this cohort was taking didanosine or stavudine; most patients had well-controlled, uncomplicated disease; and although we considered exposure to pyrazinamide and ethambutol, too few patients were exposed to distinguish significant effects. It is possible that we found no effect of protease inhibitors because the study was underpowered or it may be that, if the cardio-metabolic side effects of these drugs are well managed according to current guidance, the resultant benefits include a decrease in the risk of gout.
Our finding suggesting a protective effect of NNRTIs probably reflects that the patients at highest risk of cardiovascular disease as defined by blood pressure, lipid profiles and obesity are being preferentially treated with NNRTIs to decrease their cardiovascular risk and, as expected, since serum urate is a marker of the metabolic syndrome, the effect is to reduce urate and accordingly decrease the risk of gout. Interestingly, Bagnis et al. 16 also reported this effect. We note with interest that gout has been described as an immune reconstitution inflammatory syndrome (IRIS) in two case reports, occurring within one month of the commencement of an ART regimen in two patients, one starting TDF, emtricitabine and efavirenz 10 and the other starting lamivudine, TDF, atazanavir and ritonavir, respectively. 11 Our study cannot provide any evidence about IRIS but, as far as is currently understood, gout is not an autoimmune disease in the same way as rheumatoid arthritis or multiple sclerosis. Furthermore, rapid cell turnover is a wellrecognised risk factor for gout and hyperuricaemia, so much so that prophylactic treatment is administered to patients starting chemotherapy for a haematological malignancy or lymphoproliferative condition.
In conclusion, this case-control study explored the prevalence of and risk factors for gout in PLHIV. We found a 2.2% prevalence of gout. As expected, co-existent hypertension is a major risk factor associated with a four-fold increased risk of gout but we found that NNRTIs were associated with a 70% reduction in the risk of gout. The cross-sectional nature of this case-control study precludes the suggestion of a cause-effect relationship, but our observations may highlight an area of interest for future research.
